Showing 8131-8140 of 8647 results for "".
- Cigna Rolls Out New Plan to Fully Cover Multi-Million Dollar Gene Therapieshttps://modernod.com/news/cigna-rolls-out-new-plan-to-fully-cover-multi-million-dollar-gene-therapies/2479539/Health insurer Cigna Corp has introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers, according to a Reuters report. Gene therapies, which in general aim to treat di
- Genentech to Present Pivitol Data for Satralizumab in Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/genentech-to-present-pivitol-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder/2476853/Genentech announced that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 11-13 in Stockholm. Presentations include complete phase 3 results from the SAkuraS
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million
- Oculus Release Myopia Master for Myopia Managementhttps://modernod.com/news/oculus-release-myopia-master-for-myopia-management/2476839/Oculus has introduced the Myopia Master, a device designed to combine all the important measurement methods of myopia management: axial length, refraction values, and the central corneal radii. The Oculus Myopia Master creates a myopia report for each patient, giving due consideration to s
- Lenstec Completes FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-fda-trial-for-sbl-3-iol/2476837/Lenstec announced that it has completed its FDA trial for the SBL-3 IOL (Segmented Bifocal Lens), an asymmetric multifocal refractive IOL designed to provide patients with superior near, intermediate, and distance vision. It also offers improved contrast sensitivity and minimizes halos and glare
- Japan Conducts World’s First Transplant With iPS Cells for Corneal Diseasehttps://modernod.com/news/japan-conducts-worlds-1st-transplant-with-ips-cells-for-corneal-disease/2476836/A research team from Japan’s Osaka University said Thursday that it has conducted the world’s first transplant for corneal disease using induced pluripotent stem (iPS) cells. The team conducted the surgery in July, allowing iPS corneal tissues to replace the current queuing for cornea
- RightEye: New Research Demonstrates Reliability of Eye Tracking Data to Identify and Measure Severity of Traumatic Brain Injurieshttps://modernod.com/news/righteye-new-research-demonstrates-reliability-of-eye-tracking-data-to-identify-and-measure-severity-of-traumatic-brain-injuries/2476832/RightEye announced the results of a recent study published in the peer-reviewed journal Concussion that shows how RightEye’s FDA-cleared technology accurately measures deficits in certain eye movements that r
- Oculus to Releases New Features for the Corvis ST at ESCRShttps://modernod.com/news/oculus-to-releases-new-features-for-the-corvis-st-at-escrs/2476829/Four new software features will be introduced in the Oculus Corvis ST at the ESCRS 2019 in Paris. These updates will further increase the number of clinical applications that can be addressed based on corneal biomechanics. They include the assessment of biomechanical stability after corneal refra
- VSY Biotechnology’s Rotaryjet Preloaded Injector Has Been Registered by the European Patent Institutehttps://modernod.com/news/vsy-biotechnologys-rotaryjet-preloaded-injector-has-been-registered-by-the-european-patent-institute/2476820/VSY Biotechnology’s invention, the Rotaryjet Preloaded Injector containing an accessory system for the storage and injection of an IOL, has been registered by the European Patent Institute (EPI). This newly patented technology minimizes the use of viscoelastic material in IOL implantation and pro
- Oxurion Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 in Combination with Ranibizumab for DMEhttps://modernod.com/news/oxurion-reports-topline-month-3-results-of-phase-2a-study-evaluating-thr-317-in-combination-with-ranibizumab-for-dme/2479545/Oxurion NV reported topline data from a phase 2a study evaluating THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of diabetic macular edema (DME). <